Blackberry, Nanthealth launch cancer genome browser

Laura Pedulli | | Health Exec | Precision Medicine

Mobile communications giant Blackberry and NantHealth, a cloud-based IT vendor, have unveiled a clinical genome browser that gives physicians access to patients’ genetic data on the BlackBerry Passport smartphone.

The NantOmics Cancer Genome Browser, which is fully encrypted, will enable deep, interactive reporting on genomics data for providers in a clinical setting. For example, it offers oncologists the ability to peer into the individual alternations that make each patient’s disease unique while highlighting treatment options, according to a press release.

On the Passport, clinicians will be able to view a patient’s chromosome at an individual base-pair level.

“BlackBerry technology has proven itself secure, reliable and powerful enough to be counted on in life-and-death situations. Its innovative form and functionality make BlackBerry Passport an ideal addition to a doctor’s medical kit,” said John Chen, Executive Chairman and CEO, BlackBerry, in a statement.

The genome browser will be demonstrated at the Consumer Electronics Show in Las Vegas next month.

 

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.